Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Entrada announces FDA removal of clinical hold on ENTR-601-44
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular ...
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Therapeutics, Inc.: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...
FierceBiotech18 小时
Entrada’s 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA批准Entrada杜氏肌营养不良症药物研究
波士顿 - 根据 InvestingPro 数据显示，市值4.76亿美元且财务状况良好的生物科技公司Entrada Therapeutics, Inc. (NASDAQ: TRDA )已获得美国食品和药物管理局（FDA）批准，可以开展其杜氏肌营养不良症（DMD）实验性治疗药物ENTR-601-44的1b期临床试验。此前，英国药品和保健品监管局也批准了相关研究。
Nasdaq21 天
Entrada Therapeutics Authorizes Phase 1/2 Clinical Trial for ENTR-601-44 to Treat Duchenne ...
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
Nasdaq21 天
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025
(TRDA), a clinical-stage biopharmaceutical company, on Monday provided an update on its upcoming Phase 1/2 clinical trial for ENTR-601-44, a treatment for Duchenne muscular dystrophy or DMD in ...
Managed Healthcare Executive12 天
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Muscular Dystrophy News21 天
Phase 1/2 trial of exon 44 skipping therapy for DMD cleared in UK
Entrada Therapeutics announced it has been cleared in the U.K. to start a Phase 1/2 clinical trial of ENTR-601-44, at increasing doses, in Duchenne muscular dystrophy (DMD) patients with a mutation in ...